title: [Expressions of miR-21, miR-155 and miR-210 in plasma of patients with lymphoma and its clinical significance].
abstract: This study was purposed to investigate the expressions of miR-21, miR-155 and miR-210 in plasma of patients with lymphoma, and explore their role played in diagnosis, evaluation of chemotherapy effect and prognosis of lymphoma. The expressions of miR-21, miR-155 and miR-210 were assayed by RT-PCR in plasma of 54 cases of lymphoma, 10 cases of lymphonode inflammation and 27 cases of normal controls. The results indicated that the expressions of miR-21, miR-155 and miR-210 in plasma of lymphoma patients were higher than those of control group and lymphonode inflammation group (P < 0.05). The expressions of miR-21 and miR-210 in plasma of control group and lymphonode inflammation group had no significant differences (P > 0.05). The expression of miR-21 in plasma of lymphoma patient group significantly correlated with their serum LDH level. The expressions of miR-21 and miR-210 in plasma of previously untreated lymphoma patient group were higher than those of the patients treated for 6 or more courses (P < 0.05). The diagnostic accuracy of miR-21, miR-155 and miR-210 used for lymphoma patients was 56, 65, 48 respectively, and reached to 83 when combined three of them. It is concluded that the expressions of miR-21, miR-155 and miR-210 in plasma of lymphoma patients were significantly higher. Detection of these 3 miRNA in plasma of patients can contribute to the clinical diagnosis, treatment and prognosis evaluation of lymphoma.
authors.affiliation: Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China.
authors.forename: Tian-Tian
authors.initials: TT
authors.lastname: Ge
authors.forename: Yong
authors.initials: Y
authors.lastname: Liang
authors.forename: Rong
authors.initials: R
authors.lastname: Fu
authors.forename: Guo-Jin
authors.initials: GJ
authors.lastname: Wang
authors.forename: Er-Bao
authors.initials: EB
authors.lastname: Ruan
authors.forename: Wen
authors.initials: W
authors.lastname: Qu
authors.forename: Xiao-Ming
authors.initials: XM
authors.lastname: Wang
authors.forename: Hong
authors.initials: H
authors.lastname: Liu
authors.forename: Yu-Hong
authors.initials: YH
authors.lastname: Wu
authors.forename: Jia
authors.initials: J
authors.lastname: Song
authors.forename: Hua-Quan
authors.initials: HQ
authors.lastname: Wang
authors.forename: Li-Min
authors.initials: LM
authors.lastname: Xing
authors.forename: Jing
authors.initials: J
authors.lastname: Guan
authors.forename: Li-Juan
authors.initials: LJ
authors.lastname: Li
authors.forename: Zong-Hong
authors.initials: ZH
authors.lastname: Shao
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D008223:Lymphoma / Q000097:blood* / Q000175:diagnosis; D008297:Male; D035683:MicroRNAs / Q000097:blood*; D008875:Middle Aged; D010949:Plasma / Q000378:metabolism*; D011379:Prognosis; D055815:Young Adult
chemical_list: C524942:MIRN155 microRNA, human; C524940:MIRN21 microRNA, human; C543800:MIRN210 microRNA, human; D035683:MicroRNAs